Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Consulting agrmnt
Director departure
Appointed director
CC transcript
Notes underwriting agrmnt
Inv. presentation
|
|
Sarepta Therapeutics, Inc. (SRPT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/04/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/02/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/09/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"AMENDMENT NO. 3 TO THE SAREPTA THERAPEUTICS, INC. 2018 EQUITY INCENTIVE Plan WHEREAS, Sarepta Therapeutics, Inc. previously adopted and approved the 2018 Equity Incentive Plan ; WHEREAS, the Plan was previously amended by that certain Amendment No. 1, approved by the Board of Directors of the Company on April 3, 2020 and the Company’s stockholders on June 4, 2020 and that certain Amendment No. 2, approved by the Board on April 5, 2022 and the Company’s stockholders on June 2, 2022; WHEREAS, pursuant to Section 20 of the Plan, the “Administrator” may amend the Plan from time to time subject to Company stockholder approval; and WHEREAS, the Board, as Administrator, has determined that it is in the best interests of the Company and its stockholders to further amend the Plan to i...",
"AMENDMENT NO. 2 TO THE SAREPTA THERAPEUTICS, INC. AMENDED AND RESTATED 2013 EMPLOYEE STOCK PURCHASE PLAN WHEREAS, Sarepta Therapeutics, Inc. previously adopted and approved the Amended and Restated 2013 Employee Stock Purchase Plan ; WHEREAS, the Plan was amended by that certain Amendment No. 1, approved by the stockholders on June 6, 2019; WHEREAS, pursuant to Section 18 of the Plan, the “Administrator” or any of its committees) may amend the Plan from time to time subject to Company stockholder approval; WHEREAS, the Board, as Administrator, has determined that it is in the best interests of the Company and its stockholders to amend the Plan to increase the number of authorized shares under the Plan by 300,000 shares of common stock of the Company, as authorized under the P..." |
|
| 04/24/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/24/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/24/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ... |
| 02/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| SANDS CAPITAL MANAGEMENT, LLC reports a 2.5% stake in Sarepta Therapeutics, Inc. |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 9.2% stake in Sarepta Therapeutics Inc. |
| 01/09/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I... |
| 12/13/2022 |
8-K
| Quarterly results |
| 11/02/2022 |
8-K
| Quarterly results |
| 11/02/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 09/19/2022 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Indenture, by and between Sarepta Therapeutics, Inc. and U. S. Bank Trust Company, National Association (including the form of the 1.250% Convertible Senior Note due 2027)",
"Purchase Agreement, among Sarepta Therapeutics, Inc. and the several Initial Purchasers named in Schedule 1 thereto for whom Goldman, Sachs & Co. LLC and J.P. Morgan Securities LLC acted as Representatives",
"Purchase Agreement, between Sarepta Therapeutics, Inc. and Michael A. Chambers Living Trust",
"Base Call Option Transaction Confirmation, between Sarepta Therapeutics, Inc. and Barclays Bank PLC",
"The cover page from this Current Report on Form 8-K, formatted in Inline XBRL",
"Base Call Option Transaction Confirmation, between Sarepta Therapeutics, Inc. and Mizuho Markets Americas LLC",
"Base Call Option Transaction Confirmation, between Sarepta Therapeutics, Inc. and Morgan Stanley & Co. LLC",
"Base Call Option Transaction Confirmation, between Sarepta Therapeutics, Inc. and RBC Capital Markets, LLC",
"Additional Call Option Transaction Confirmation, between Sarepta Therapeutics, Inc. and Barclays Bank PLC",
"Additional Call Option Transaction Confirmation, between Sarepta Therapeutics, Inc. and Goldman Sachs & Co. LLC" |
|
| 08/02/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/02/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 06/03/2022 |
8-K
| Quarterly results |
| 05/04/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/25/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/21/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/02/2022 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 03/01/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 02/11/2022 |
SC 13G
| SANDS CAPITAL MANAGEMENT, LLC reports a 6.2% stake in SAREPTA THERAPEUTICS INC |
| 02/11/2022 |
SC 13G
| JANUS HENDERSON GROUP PLC reports a 8.3% stake in SAREPTA THERAPEUTICS, INC. |
| 02/10/2022 |
SC 13G/A
| VANGUARD GROUP INC reports a 9.5% stake in Sarepta Therapeutics Inc. |
| 02/09/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/10/2022 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I... |
| 11/17/2021 |
8-K
| Appointed a new director |
| 11/03/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 10/15/2021 |
8-K
| Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements...|
Docs:
|
"Underwriting Agreement, October 13, 2021 among Sarepta Therapeutics, Inc. and Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Credit Suisse Securities (USA) LLC, as representatives of the underwriters named therein",
"Opinion of Ropes & Gray LLP",
"Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quarter Ended September 30, 2021",
"Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock",
"Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock" |
|
|
|
|